Related Experiment Video
Updated: Aug 8, 2026

Murine Dermal Fibroblast Isolation by FACS
Published on: January 7, 2016
Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis
James S Hagood1, Priya Prabhakaran, Pallavi Kumbla
1Department of Pediatrics, University of Alabama, Birmingham, USA. jhagood@peds.uab.edu
Insights
Thy-1 glycoprotein loss on lung fibroblasts enhances fibrotic responses. This study reveals Thy-1-negative fibroblasts drive lung fibrosis by increasing transforming growth factor-beta activation.
Area of Science:
- Cell Biology
- Immunology
- Pulmonary Medicine
Background:
- Fibroblasts exhibit diverse subpopulations crucial for fibrotic responses.
- Thy-1 glycoprotein expression on fibroblasts modulates fibrogenic potential.
- Previous work linked Thy-1 deficiency to enhanced proliferation and TGF-beta activation.
Purpose of the Study:
- To investigate the role of Thy-1 glycoprotein in modulating lung fibroblast activity during fibrotic responses.
- To determine if Thy-1 expression influences the severity of bleomycin-induced lung fibrosis.
- To explore the relationship between Thy-1 expression and myofibroblast differentiation in pulmonary fibrosis.
Main Methods:
- Comparison of lung fibrosis severity in Thy-1 knockout (Thy-1-/-) and wild-type mice after bleomycin challenge.
- Assessment of transforming growth factor-beta (TGF-beta) activation and collagen accumulation in lung tissue.
- Immunohistochemical analysis of Thy-1 expression in mouse lung lesions and human idiopathic pulmonary fibrosis samples.
- In vitro experiments assessing the effect of fibrogenic cytokines (IL-1, TNF-alpha) on fibroblast Thy-1 expression and differentiation.
Main Results:
- Thy-1-/- mice exhibited exacerbated lung fibrosis, increased collagen deposition, and heightened TGF-beta activation post-bleomycin exposure.
- Thy-1-negative cells were the predominant population showing TGF-beta activation and myofibroblast differentiation in fibrotic lesions.
- Human idiopathic pulmonary fibrosis tissues showed absent Thy-1 staining in fibroblastic foci, unlike normal lung fibroblasts which were Thy-1 positive.
- In vitro, fibrogenic cytokines induced loss of fibroblast Thy-1 expression, correlating with Smad phosphorylation and myofibroblast differentiation.
Conclusions:
- Loss of Thy-1 surface expression on lung fibroblasts is induced by fibrogenic injury.
- Reduced Thy-1 expression promotes enhanced fibrogenesis by facilitating TGF-beta activation and myofibroblast differentiation.
- Thy-1 serves as a critical regulator of fibroblast behavior in the context of pulmonary fibrosis.
Abstract:
Fibroblasts consist of heterogeneous subpopulations that have distinct roles in fibrotic responses. Previously we reported enhanced proliferation in response to fibrogenic growth factors and selective activation of latent transforming growth factor (TGF)-beta in fibroblasts lacking cell surface expression of Thy-1 glycoprotein, suggesting that Thy-1 modulates the fibrogenic potential of fibroblasts. Here we report that compared to controls Thy-1-/- C57BL/6 mice displayed more severe histopathological lung fibrosis, greater accumulation of lung collagen, and increased TGF-beta activation in the lungs 14 days after intratracheal bleomycin. The majority of cells demonstrating TGF-beta activation and myofibroblast differentiation in bleomycin-induced lesions were Thy-1-negative. Histological sections from patients with idiopathic pulmonary fibrosis demonstrated absent Thy-1 staining within fibroblastic foci. Normal lung fibroblasts, in both mice and humans, were predominantly Thy-1-positive. The fibrogenic cytokines interleukin-1 and tumor necrosis factor-alpha induced loss of fibroblast Thy-1 surface expression in vitro, which was associated with Thy-1 shedding, Smad phosphorylation, and myofibroblast differentiation. These results suggest that fibrogenic injury promotes loss of lung fibroblast Thy-1 expression, resulting in enhanced fibrogenesis.
Related Concept Videos
Introduction to Fibroblasts
TGF - β Signaling Pathway
Cirrhosis II: Pathophysiology

